Foam dressing with integral porous film

Information

  • Patent Grant
  • 9289328
  • Patent Number
    9,289,328
  • Date Filed
    Wednesday, November 13, 2013
    11 years ago
  • Date Issued
    Tuesday, March 22, 2016
    8 years ago
Abstract
Wound dressings and wound inserts comprising a porous film layer and at least a channel, wound inserts of forming wound inserts comprising a porous film layer and at least a channel, and wound-treatment wound inserts.
Description
BACKGROUND

1. Field of the Invention


The present invention relates generally to healing of wounds and wound-treatment therapies. More particularly, but not by way of limitation, the present invention relates to fluid-instillation and negative-pressure wound therapies.


2. Background Information


Clinical studies and practice have shown that providing a reduced pressure in proximity to a tissue site augments and accelerates the growth of new tissue at the tissue site. The applications of this phenomenon are numerous, but application of reduced pressure has been particularly successful in treating wounds. This treatment (frequently referred to in the medical community as “negative pressure wound therapy,” “reduced pressure therapy,” or “vacuum therapy”) provides a number of benefits, including faster healing and increased formulation of granulation tissue. Typically, reduced pressure is applied to tissue through a wound insert (e.g., a porous pad or other manifold device). The wound insert typically contains cells or pores that are capable of distributing reduced pressure to the tissue and channeling fluids that are drawn from the tissue. The wound insert can be incorporated into a wound dressing having other components that facilitate treatment, such as, for example, a drape (e.g., adhesive surgical drape). Instillation fluids (e.g., irrigation fluids and/or medicaments) may be used in conjunction with negative pressure wound therapy to promote healing and/or improve efficacy. One example of a system for delivering active solutions to a wound is disclosed in U.S. Pat. No. 6,398,767.


In certain applications, providing negative pressure to the wound site is clinically advantageous, but formation of granulation tissue is undesirable. For example, providing negative pressure to orthopedic cavity wounds containing hardware such as plates, rods, or pins may help these wounds heal faster. However, the formation of granulation tissue around this hardware can be harmful.


SUMMARY

Wound inserts, and methods for making and using them, are presented.


Some embodiments of a method of manufacturing a wound insert comprise obtaining a member comprising open-celled reticulated foam, the member further comprising a first surface, a second surface, and an uncompressed thickness; obtaining a platen press comprising a first platen and a second platen; heating the first platen to a first temperature; placing the member in the platen press such that the first surface faces the first platen and the second surface faces the second platen; and compressing the member to a compressed thickness for a compression time.


Additionally, some embodiments may further comprise the step of forming a porous film layer on the first surface of the member. Other embodiments may further comprise the step of forming a porous film layer on the second surface of the member. Still other embodiments may further comprise removing a portion of the porous film layer from the first surface. The removing step may comprise laser cutting, laser etching, die cutting, or water cutting. Still other embodiments may further comprise forming channels in the porous film layer.


In certain embodiments, the compressed thickness is less than about one-tenth, one-ninth, one-eighth, one-seventh, one-sixth, or one-fifth the uncompressed thickness. In some embodiments, the uncompressed thickness is about 0.5 inch and the compressed thickness is about 0.05 inch. In some embodiments, the first platen, the second platen, or both may be heated to a temperature between about 160° C. and about 180° C.; in specific embodiments, the platen may be heated to a temperature of about 175° C. The compression time may between about 15 minutes and about 30 minutes.


In some embodiments, the member may comprise polyurethane, such as polyurethane-polyester or polyurethane-polyether; polyolefins, such as polypropylenes (PP) or polyethylenes (PE); silicone polymers; polyvinylchloride; polyamides; polyesters; acrylics; thermoplastic elastomers such as styrene-butene-styrene (SBS) or styrene-ethylene-butene-styrene (SEBS); polyether-amide block copolymers (PEBAX); elastomers such as styrene butadiene rubber (SBR); ethylene propylene rubber (EPR); ethylene propylene diene modified rubber (EPDM); natural rubber (NR); ethylene vinyl acetate (EVA); polyvinyl alcohol (PVOH); polyvinyl acetal; or polyvinyl butyral (PVB). Additionally, foam member may comprise a bioabsorbable polymer, examples of which include polylactic acid, polylactide (PLA), polyglycolic acid, polyglycolide (PGA), and polycaprolactone (PCL).


Other embodiments of a method of manufacturing a wound insert comprise the steps of obtaining an open-celled reticulated foam member having a first surface, a second surface, and a thickness between the first and second surfaces; felting the first surface of the member to form a felted layer; and forming at least one channel in the felted layer.


In certain embodiments, the at least one channel may be in fluid communication with the second layer through the thickness. The felting step may further comprise applying heat and pressure to the member. In some embodiments, forming may comprise laser cutting, water cutting, or die cutting.


The member may comprise polyurethane, such as polyurethane-polyester or polyurethane-polyether; polyolefins, such as polypropylenes (PP) or polyethylenes (PE); silicone polymers; polyvinylchloride; polyamides; polyesters; acrylics; thermoplastic elastomers such as styrene-butene-styrene (SBS) or styrene-ethylene-butene-styrene (SEBS); polyether-amide block copolymers (PEBAX); elastomers such as styrene butadiene rubber (SBR); ethylene propylene rubber (EPR); ethylene propylene diene modified rubber (EPDM); natural rubber (NR); ethylene vinyl acetate (EVA); polyvinyl alcohol (PVOH); polyvinyl acetal; or polyvinyl butyral (PVB). Additionally, foam member may comprise a bioabsorbable polymer, examples of which include polylactic acid, polylactide (PLA), polyglycolic acid, polyglycolide (PGA), and polycaprolactone (PCL).


Certain embodiments are directed to a wound insert. Some embodiments comprise open-celled reticulated foam comprising a first surface, a second surface and a thickness between the first and second surfaces, wherein the first surface of the open-celled reticulated foam comprises a porous film layer and at least one channel.


Embodiments of a wound insert may comprise polyurethane-polyester or polyurethane-polyether; polyolefins, such as polypropylenes (PP) or polyethylenes (PE); silicone polymers; polyvinylchloride; polyamides; polyesters; acrylics; thermoplastic elastomers such as styrene-butene-styrene (SBS) or styrene-ethylene-butene-styrene (SEBS); polyether-amide block copolymers (PEBAX); elastomers such as styrene butadiene rubber (SBR); ethylene propylene rubber (EPR); ethylene propylene diene modified rubber (EPDM); natural rubber (NR); ethylene vinyl acetate (EVA); polyvinyl alcohol (PVOH); polyvinyl acetal; or polyvinyl butyral (PVB). Additionally, foam member may comprise a bioabsorbable polymer, examples of which include polylactic acid, polylactide (PLA), polyglycolic acid, polyglycolide (PGA), and polycaprolactone (PCL).


Other embodiments of a wound insert may comprise an open-celled reticulated foam member comprising a porous film layer, the porous film layer comprising a film thickness; and at least a channel in the porous film layer, wherein the at least one channel comprises a channel depth, the channel depth being equal to or greater than the film thickness; where the wound insert is configured to be disposed between a wound of a patient and a drape coupled to the skin adjacent to the wound.


Specific embodiments may further comprise at least a sealed edge joining first and second surfaces. In various embodiments, the open-celled reticulated foam member may comprise polyurethane-polyester or polyurethane-polyether; polyolefins, such as polypropylenes (PP) or polyethylenes (PE); silicone polymers; polyvinylchloride; polyamides; polyesters; acrylics; thermoplastic elastomers such as styrene-butene-styrene (SBS) or styrene-ethylene-butene-styrene (SEBS); polyether-amide block copolymers (PEBAX); elastomers such as styrene butadiene rubber (SBR); ethylene propylene rubber (EPR); ethylene propylene diene modified rubber (EPDM); natural rubber (NR); ethylene vinyl acetate (EVA); polyvinyl alcohol (PVOH); polyvinyl acetal; or polyvinyl butyral (PVB). Additionally, foam member may comprise a bioabsorbable polymer, examples of which include polylactic acid, polylactide (PLA), polyglycolic acid, polyglycolide (PGA), and polycaprolactone (PCL).


Still other embodiments are directed to methods for removing fluids from a wound site. Certain embodiments of a method for removing a fluid from a wound site may comprise the steps of obtaining a wound insert comprising an open-celled reticulated foam member comprising a porous film layer, the porous film layer comprising a film thickness; and at least a channel comprising a channel depth, the channel depth being equal to or greater than the film thickness; obtaining a patient having a wound; inserting the wound insert into the wound such that the porous film layer faces the wound; applying a drape such that the wound insert is disposed between the drape and the wound, and the drape is coupled to skin adjacent the wound; obtaining a vacuum source coupled to the wound insert; and applying negative pressure to the wound insert.


Other embodiments may comprise the steps of obtaining a wound insert comprising an open-celled reticulated foam member comprising a porous film layer, the porous film layer comprising a film thickness; and at least a channel comprising a channel depth, the channel depth being equal to or greater than the film thickness; obtaining a patient having a wound; inserting the wound insert into the wound such that the porous film layer faces the wound; applying a drape such that the wound insert is disposed between the drape and the wound, and the drape is coupled to skin adjacent the wound; and actuating a fluid source coupled to the wound insert such that fluid is delivered to the wound insert.


The following drawings illustrate by way of example and not limitation. For the sake of brevity and clarity, every feature of a given structure is not always labeled in every figure in which that structure appears. Identical reference numbers do not necessarily indicate an identical structure. Rather, the same reference number may be used to indicate a similar feature or a feature with similar functionality, as may non-identical reference numbers.





BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings illustrate by way of example and not limitation. For the sake of brevity and clarity, every feature of a given structure is not always labeled in every figure in which that structure appears. Identical reference numbers do not necessarily indicate an identical structure. Rather, the same reference number may be used to indicate a similar feature or a feature with similar functionality, as may non-identical reference numbers.



FIG. 1 illustrates an embodiment of a method of making a wound insert.



FIG. 2A illustrates a perspective view of an embodiment of a foam member.



FIG. 2B illustrates a side view of embodiment of a foam member.



FIG. 3A illustrates a schematic view, of an embodiment of an uncompressed foam member in a press.



FIG. 3B illustrates a schematic view of an embodiment of a compressed foam member in a press.



FIG. 4 illustrates a side view of an embodiment of a wound insert.



FIG. 5A illustrates a perspective view of an embodiment of a wound insert comprising a plurality of channels.



FIG. 5B illustrates a perspective view of an embodiment of a wound insert comprising a channel.



FIG. 6A illustrates a side view of a wound insert comprising a plurality of channels.



FIG. 6B illustrates a side view of a wound insert comprising a plurality of channels.



FIG. 7 illustrates a schematic diagram of a wound insert in a wound.





DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

The term “coupled” is defined as connected, although not necessarily directly, and not necessarily mechanically; two items that are “coupled” may be integral with each other. The terms “a” and “an” are defined as one or more unless this disclosure explicitly requires otherwise. The terms “substantially,” “approximately,” and “about” are defined as largely but not necessarily wholly what is specified, as understood by a person of ordinary skill in the art.


The terms “comprise” (and any form of comprise, such as “comprises” and “comprising”), “have” (and any form of have, such as “has” and “having”), “include” (and any form of include, such as “includes” and “including”) and “contain” (and any form of contain, such as “contains” and “containing”) are open-ended linking verbs. As a result, a wound-treatment method that “comprises,” “has,” “includes” or “contains” one or more steps possesses those one or more steps, but is not limited to possessing only those one or more steps. Likewise, a wound dressing that “comprises,” “has,” “includes” or “contains” one or more elements possesses those one or more elements, but is not limited to possessing only those elements. For example, in a wound dressing that comprises one of the present wound inserts and a drape, the wound dressing includes the specified elements but is not limited to having only those elements. For example, such a wound dressing could also include a connection pad configured to be coupled to a negative pressure wound therapy (NPWT) apparatus (e.g., including a vacuum source and/or a fluid source).


Further, a device or structure that is configured in a certain way is configured in at least that way, but it can also be configured in other ways than those specifically described.


Referring now to FIGS. 1-3B, embodiments of a foam dressing 8 and methods for manufacturing such a dressing are shown.



FIGS. 2A and 2B depict perspective and side views of an open-celled reticulated foam member 10, having a first surface 12, a second surface 14, sides 11, and edges 13. Foam member 10 may be of any suitable shape, including a rectangular prism or a cylinder. In certain applications, foam member 10 may comprise a regular or irregular polygon having a depth, depending on the shape of the wound into which it is intended to be inserted. One of skill in the art will appreciate that the dimensions of foam member 10 in the accompanying figures have been exaggerated for clarity.


An open-celled reticulated foam has a netlike microstructure, with few if any closed cells. In certain embodiments, the porosity can range from 95%-98%, though less porous or more porous foams may be used. In certain embodiments, foam member 10 may comprise a polyurethane, such as polyurethane-polyester or polyurethane-polyether; polyolefins, such as polypropylenes (PP) or polyethylenes (PE); silicone polymers; polyvinylchloride; polyamides; polyesters; acrylics; thermoplastic elastomers such as styrene-butene-styrene (SBS) or styrene-ethylene-butene-styrene (SEBS); polyether-amide block copolymers (PEBAX); elastomers such as styrene butadiene rubber (SBR); ethylene propylene rubber (EPR); ethylene propylene diene modified rubber (EPDM); natural rubber (NR); ethylene vinyl acetate (EVA); polyvinyl alcohol (PVOH); polyvinyl acetal; or polyvinyl butyral (PVB). Additionally, foam member 10 may comprise a bioabsorbable polymer, examples of which include polylactic acid, polylactide (PLA), polyglycolic acid, polyglycolide (PGA), and polycaprolactone (PCL). Methods of manufacturing open-celled reticulated foam are well known. Open-celled reticulated foam is commercially available from a variety of sources, including Kinetic Concepts, Inc., San Antonio, Tex., <www.kcil.com>, 1-800-275-4524.


In the embodiments shown in FIGS. 2A and 2B, first surface 12, second surface 14, and sides 11 of foam member 10 are unfinished. In other words, reticulated cells extend to all surfaces of the foam member. In certain applications, these unfinished surfaces allow negative pressure to be applied to the wound site and encourage granulation tissue to grow into the foam member, which may be desirable depending on the nature of the wound. In other applications, however, the formation of granulation tissue in the foam member may complicate or impede the healing process, even though it would be desirable to provide negative pressure to the wound site. As discussed in more detail below, certain surfaces may be left unfinished if it is desirable that granulation tissue grows into them.


Referring now to FIGS. 3A and 3B, foam member 10 having an uncompressed thickness U is shown schematically between a first platen 22 and a second platen 24 in a press (not shown). Suitable presses are commercially available from numerous sources, including Carver Press, Wabash, Ind. <www.carverpress.com>. First platen 22, second platen 24, or both may be capable of being heated to a specified temperature. In the embodiment shown, first platen 22 is heated to a specified temperature. In certain embodiments, the temperature may range between 160° C. and 180° C., depending on the foam used. Foam member 10 is placed in the press such that first surface 12 faces first platen 22, and second surface 14 faces second platen 24. The platens 22, 24 are brought together, compressing foam member 10 to a compressed thickness C. Compressed thickness C of foam member 10 is a fraction of uncompressed thickness U. In certain embodiments, compressed thickness C may be less than one-tenth, one-ninth, one-eighth, one-seventh, one-sixth or one-fifth uncompressed thickness U.


Porous film layer 16 is formed by applying heat and pressure to the foam member; such application of heat and pressure is sometimes known as “felting.” Porous film layer 16 is sometimes known as a “felted layer.” In such a process, foam member 10 is held in a compressed position between first platen 22 and second platen 24 for a specified period of time. In certain embodiments, the period of time ranges between 15 and 30 minutes, though the time period may be more or less depending on the material used for foam member 10. Generally, the lower the temperature of the platen, the longer foam member 10 must be held in compression. Overheating the platen, or applying pressure for too long, may risk damaging foam member 10 by charring or burning it.


After the specified time period has elapsed, foam member 10 may be removed from the press. As shown in FIG. 4, the pressure and heat will form a porous film layer 16 on first surface 12 having thickness F. Porous film layer 16 is integral with foam member 10. In other words, porous film layer 16 and foam member 10 form a single unitary body. Porous film layer 16 will be comparatively smoother than any unfinished or non-felted surface, such as second surface 14 in the embodiment shown. Further, the pores in porous film layer 16 are substantially smaller than the pores throughout foam member 10 in general or on any non-felted side.


In certain embodiments, it may be desirable to form a porous film layer on second surface 14 of foam member 10. Those of skill in the art will understand that it is possible to form porous film layers on first surface 12 as well as on second surface 14. Methods of forming a porous film layer 16 include heating both platens before compressing foam member 10, or first compressing and heating one side then compressing and heating the other side. In such embodiments, the porous film layer formed on second surface 14 is integral with foam member 10. That is, the porous film later formed on second surface 14 and foam member 10 comprise a single unitary body.


Perspective views and side views of various embodiments of wound insert 8 are shown in FIGS. 5A-6B. First surface 12 of wound insert 8 comprises porous film layer 16 that intersects with sides 11 at edges 13, as well as one or more channels 18. Channels 18 may take a variety of shapes, including straight, curved, zig-zag, spiral, circular, or any fanciful shape. As shown in FIG. 5A, channels 18 may run to edge 13, or may be self-contained on first surface 12. The exact shape of channels 18 may be configured for optimal fluid removal or fluid instillation at the wound site. As shown in FIGS. 6A and 6B, the depth of channels 18 may be about equal to thickness F of film layer 16. In other embodiments, the depth of channels 18 may be greater than thickness F of film layer 16. And in still other embodiments, the depth of channels 18 may be less than the thickness F of film layer 16.


In certain embodiments, channels 18 may be formed on first surface 12 by removing portions of porous film layer 16. In some embodiments, portions of porous film layer 16 may be removed with a laser cutter (not shown). In one example, the desired channel pattern is drawn in a CAD program. The channel pattern may be transmitted to a computer-controlled laser cutter, which then applies a laser beam to the porous film layer 16 of the wound insert 8. An advantage of using a laser cutter instead of other methods to remove material is that the focal depth of the laser is easily adjusted, and thus the depth of channels 18 may be precisely controlled. A laser may be more easily adjusted to remove material only from porous film layer 16, and not from foam member 10. Additionally, a laser with an adjustable focal depth may more easily create channels 18 having different depths: for example, some channels 18 may have a depth equivalent to thickness F of porous film layer 16, while other channels 18 may have a depth greater than F. Other material-removal processes may be used, however. For example, a water jet cutter, a die press, or etching may be used to remove material from porous film layer.


Channels 18 may also be formed in other ways, such as by molding. A mold with the desired channel pattern may be coupled to one or both platens during the heating and compression steps. In certain embodiments, use of a mold will prevent porous film from being formed in the channels 18. In other embodiments, channels 18 may comprise a layer of porous film 16.


Referring again to FIGS. 6A and 6B, cross-sectional views of a wound insert are shown. As shown in FIG. 6A, in some embodiments, sides 11 are unfinished, such that the open-celled reticulated foam member 10 is exposed. As shown in FIG. 6B, in other embodiments, sides 11 are finished with a seal or seam 15. Sides 11 or second surface 14 may be finished or unfinished depending on the desired application. Leaving sides 11 or surface 14 unfinished may encourage granulation tissue growth into foam member 10. Sealing or seaming or otherwise finishing sides 11 or surface 14 will prevent such tissue growth. Granulation tissue growth is desirable in some instances but not in others.


Referring now to FIG. 7, wound insert 8 is shown as part of a wound treatment system 30. In the embodiment shown, wound insert 8 is shown placed in wound 50 of a patient (not shown) such that first surface 12 comprising porous film layer 16 and channels 18 faces the wound surface 52. In other embodiments, wound insert 8 may comprise more than one porous film layer 16 disposed on, for example, second surface 14; these additional porous film layer(s) 16 may or many not include channels 18.


A drape 32 is placed over wound 50 and wound insert 8 such that wound insert 8 is between drape 32 and wound 50. Drape 32 is coupled to the skin 54 of the patient. Wound insert 8 is coupled to a wound treatment apparatus 42 by conduit 36. Apparatus 42 may comprise a vacuum source configured to apply negative pressure to wound insert 8 through conduit 36. Apparatus 42 may further comprise a fluid source configured to deliver a fluid through conduit 36 to wound insert 8. For example, apparatus 42 may comprise a pump configured to pump a fluid through conduit 36 to wound insert 8. Examples of such fluids include a medicinal fluids, antibacterial fluids, or irrigation fluids. Various wound therapy systems and components are commercially available through and/or from KCI USA, Inc. of San Antonio, Tex., U.S.A.


Conduit 36 can comprise a single lumen conduit (e.g., switched between a vacuum source and/or a fluid source) or can comprise multiple single-lumen conduits or a multi-lumen conduit such that, for example, fluid can be delivered and/or negative pressure can be applied to wound insert 8 individually or simultaneously. Or conduit 36 can comprise multiple lumens (e.g., as in a single conduit with a central limit for application of negative, pressure and/or fluid delivery and one or more peripheral lumens disposed adjacent or around the central lumen such that the peripheral lumens can be coupled to a pressure sensor to sense and/or detect a pressure or negative pressure between drape 32 and wound surface 52. In the embodiment shown, system 30 further comprises a wound dressing connection pad 34 configured to be coupled (and is shown coupled) to conduit 36. One example of a suitable connection pad 36 is the “V.A.C. T.R.A.C.® Pad,” commercially available from KCI USA, Inc. of San Antonio, Tex., U.S.A. One example of a suitable drape 32 includes the “V.A.C.® Drape” commercially available from KCI USA, Inc. (and its affiliates) of San Antonio, Tex., U.S.A.


Channels 18 provide a path of lower resistance between second surface 14 through foam member 10 as compared to the path through porous film 16. Thus, when a fluid is instilled through wound insert 8, most or all of the fluid will tend to flow into wound 50 through channels 18. And conversely, when fluids are being removed from wound 50, much or all of the fluid will flow up through channels 18, through foam member 10, and into conduit 36.


The various illustrative embodiments of devices, systems, and methods described herein are not intended to be limited to the particular forms disclosed. Rather, they include all modifications and alternatives falling within the scope of the claims.


The claims are not intended to include, and should not be interpreted to include, means-plus- or step-plus-function limitations, unless such a limitation is explicitly recited in a given claim using the phrase(s) “means for” or “step for,” respectively.

Claims
  • 1. A method of manufacturing a wound insert comprising: obtaining an open-celled reticulated foam member having a first surface, a second surface, and a thickness between the first and the second surface;felting the first surface of the foam member to form a felted layer; andremoving a portion of the felted layer from the first surface to form at least one channel in the felted layer, the at least one channel being configured to communicate fluid from a wound and to deliver fluid to the wound.
  • 2. The method of claim 1, wherein the at least one channel is in fluid communication with the second surface through the thickness.
  • 3. The method of claim 1, wherein felting further comprises applying heat and pressure to the foam member.
  • 4. A wound insert comprising: an open-celled reticulated foam member comprising: a first surface and a second surface, the first surface comprising a porous film layer configured to allow passage of negative pressure to a wound site and to inhibit tissue ingrowth; a thickness between the first and the second surface; the porous film layer comprising a film thickness; and at least one channel formed in the porous film layer and comprising a channel depth equal to or greater than the film thickness.
  • 5. The wound insert of claim 4, wherein the foam member and the porous film layer each comprise pores, and wherein the pores in the porous film layer are substantially smaller than the pores in the foam member.
  • 6. The wound insert of claim 4, wherein the wound insert is configured to be disposed between a wound of a patient and a drape coupled to skin adjacent to the wound.
  • 7. The method of claim 1, wherein felting the first surface comprises: obtaining a platen press comprising a first platen and a second platen;heating the first platen to a first temperature;placing the foam member in the platen press such that the first surface faces the first platen and the second surface faces the second platen; andcompressing the foam member to a compressed thickness for a compression time.
  • 8. The method of claim 1, wherein felting the first surface forms a porous film layer on the first surface of the foam member, the porous film layer being configured to allow the passage of negative pressure and to inhibit tissue ingrowth.
  • 9. A method of manufacturing a wound insert, comprising: felting a surface of an open-celled reticulated foam member to form a felted layer extending into the foam member from the surface; andremoving a portion of the felted layer from the surface to form at least one channel in the felted layer.
  • 10. The method of claim 9, wherein the surface of the foam member is a first surface, and wherein the method further comprises felting a second surface of the foam member.
  • 11. The method of claim 9, wherein the step of felting is performed by compressing the foam member and heating the surface.
  • 12. The method of claim 9, wherein the at least one channel has a depth substantially equal to a depth of the felted layer.
  • 13. The method of claim 9, wherein the at least one channel has a depth greater than a depth of the felted layer.
  • 14. The method of claim 9, wherein the at least one channel is formed by cutting to remove material from the felted layer.
  • 15. The method of claim 9, wherein the at least one channel is formed by molding.
  • 16. The wound insert of claim 4, the at least one channel defined by material removed from the porous film layer.
CROSS-REFERENCE TO RELATED APPLICATION

This application is a divisional application of U.S. patent application Ser. No. 13/316,997, filed Dec. 12, 2011, which claims priority to U.S. Provisional Patent Application Ser. No. 61/423,405, filed Dec. 15, 2010. Each of the above-referenced applications are incorporated herein be reference for all purposes.

US Referenced Citations (106)
Number Name Date Kind
1355846 Rannells Oct 1920 A
2547758 Keeling Apr 1951 A
2632443 Lesher Mar 1953 A
2682873 Evans et al. Jul 1954 A
2910763 Lauterbach Nov 1959 A
2969057 Simmons Jan 1961 A
3066672 Crosby, Jr. et al. Dec 1962 A
3367332 Groves Feb 1968 A
3520300 Flower, Jr. Jul 1970 A
3568675 Harvey Mar 1971 A
3648692 Wheeler Mar 1972 A
3682180 McFarlane Aug 1972 A
3826254 Mellor Jul 1974 A
4080970 Miller Mar 1978 A
4096853 Weigand Jun 1978 A
4139004 Gonzalez, Jr. Feb 1979 A
4165748 Johnson Aug 1979 A
4184510 Murry et al. Jan 1980 A
4233969 Lock et al. Nov 1980 A
4245630 Lloyd et al. Jan 1981 A
4256109 Nichols Mar 1981 A
4261363 Russo Apr 1981 A
4275721 Olson Jun 1981 A
4284079 Adair Aug 1981 A
4297995 Golub Nov 1981 A
4333468 Geist Jun 1982 A
4373519 Errede et al. Feb 1983 A
4382441 Svedman May 1983 A
4392853 Muto Jul 1983 A
4392858 George et al. Jul 1983 A
4419097 Rowland Dec 1983 A
4465485 Kashmer et al. Aug 1984 A
4475909 Eisenberg Oct 1984 A
4480638 Schmid Nov 1984 A
4525166 Leclerc Jun 1985 A
4525374 Vaillancourt Jun 1985 A
4540412 Van Overloop Sep 1985 A
4543100 Brodsky Sep 1985 A
4548202 Duncan Oct 1985 A
4551139 Plaas et al. Nov 1985 A
4569348 Hasslinger Feb 1986 A
4605399 Weston et al. Aug 1986 A
4608041 Nielson Aug 1986 A
4640688 Hauser Feb 1987 A
4655754 Richmond et al. Apr 1987 A
4664662 Webster May 1987 A
4710165 McNeil et al. Dec 1987 A
4733659 Edenbaum et al. Mar 1988 A
4743232 Kruger May 1988 A
4758220 Sundblom et al. Jul 1988 A
4787888 Fox Nov 1988 A
4826494 Richmond et al. May 1989 A
4838883 Matsuura Jun 1989 A
4840187 Brazier Jun 1989 A
4863449 Therriault et al. Sep 1989 A
4872450 Austad Oct 1989 A
4878901 Sachse Nov 1989 A
4897081 Poirier et al. Jan 1990 A
4906233 Moriuchi et al. Mar 1990 A
4906240 Reed et al. Mar 1990 A
4919654 Kalt et al. Apr 1990 A
4941882 Ward et al. Jul 1990 A
4953565 Tachibana et al. Sep 1990 A
4969880 Zamierowski Nov 1990 A
4985019 Michelson Jan 1991 A
5037397 Kalt et al. Aug 1991 A
5086170 Luheshi et al. Feb 1992 A
5092858 Benson et al. Mar 1992 A
5100396 Zamierowski Mar 1992 A
5134994 Say Aug 1992 A
5149331 Ferdman et al. Sep 1992 A
5167613 Karami et al. Dec 1992 A
5176663 Svedman et al. Jan 1993 A
5215522 Page et al. Jun 1993 A
5232453 Plass et al. Aug 1993 A
5261893 Zamierowski Nov 1993 A
5278100 Doan et al. Jan 1994 A
5279550 Habib et al. Jan 1994 A
5298015 Komatsuzaki et al. Mar 1994 A
5342376 Ruff Aug 1994 A
5344415 DeBusk et al. Sep 1994 A
5358494 Svedman Oct 1994 A
5437622 Carion Aug 1995 A
5437651 Todd et al. Aug 1995 A
5527293 Zamierowski Jun 1996 A
5549584 Gross Aug 1996 A
5556375 Ewall Sep 1996 A
5607388 Ewall Mar 1997 A
5626814 Vicino May 1997 A
5636643 Argenta et al. Jun 1997 A
5645081 Argenta et al. Jul 1997 A
6071267 Zamierowski Jun 2000 A
6135116 Vogel et al. Oct 2000 A
6241747 Ruff Jun 2001 B1
6287316 Agarwal et al. Sep 2001 B1
6345623 Heaton et al. Feb 2002 B1
6488643 Tumey et al. Dec 2002 B1
6493568 Bell et al. Dec 2002 B1
6553998 Heaton et al. Apr 2003 B2
6814079 Heaton et al. Nov 2004 B2
20020077661 Saadat Jun 2002 A1
20020115951 Norstrem et al. Aug 2002 A1
20020120185 Johnson Aug 2002 A1
20020143286 Tumey Oct 2002 A1
20060079852 Bubb et al. Apr 2006 A1
20090287129 Boehringer et al. Nov 2009 A1
Foreign Referenced Citations (34)
Number Date Country
550575 Mar 1986 AU
745271 Apr 1999 AU
755496 Feb 2002 AU
2005436 Jun 1990 CA
26 40 413 Mar 1978 DE
43 06 478 Sep 1994 DE
295 04 378 Oct 1995 DE
0100148 Feb 1984 EP
0117632 Sep 1984 EP
0161865 Nov 1985 EP
0358302 Mar 1990 EP
1018967 Aug 2004 EP
692578 Jun 1953 GB
2 195 255 Apr 1988 GB
2 197 789 Jun 1988 GB
2 220 357 Jan 1990 GB
2 235 877 Mar 1991 GB
2 329 127 Mar 1999 GB
2 333 965 Aug 1999 GB
4129536 Apr 1992 JP
71559 Apr 2002 SG
8002182 Oct 1980 WO
8704626 Aug 1987 WO
9010424 Sep 1990 WO
9309727 May 1993 WO
9420041 Sep 1994 WO
9605873 Feb 1996 WO
9718007 May 1997 WO
9913793 Mar 1999 WO
0061206 Oct 2000 WO
2009158124 Dec 2009 WO
2009158128 Dec 2009 WO
2010033613 Mar 2010 WO
2011090991 Jul 2011 WO
Non-Patent Literature Citations (39)
Entry
N.A. Bagautdinov, “Variant of External Vacuum Aspiration in the Treatment of Purulent Diseases of the Soft Tissues,” Current Problems in Modern Clinical Surgery: Interdepartmental Collection, edited by V. Ye Volkov et al. (Chuvashia State University, Cheboksary, U.S.S.R. 1986);pp. 94-96 (certified translation).
Louis C. Argenta, MD and Michael J. Morykwas, PhD; “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Animal Studies & Basic Foundation”; Annals of Plastic Surgery, vol. 38, No. 6, Jun. 1997; pp. 553-562.
Susan Mendez-Eastmen, RN; “When Wounds Won't Heal” RN Jan. 1998, vol. 61 (1); Medical Economics Company, Inc., Montvale, NJ, USA; pp. 20-24.
James H. Blackburn, II, MD, et al; “Negative-Pressure Dressings as a Bolster for Skin Grafts”; Annals of Plastic Surgery, vol. 40, No. 5, May 1998, pp. 453-457.
John Masters; “Reliable, Inexpensive and Simple Suction Dressings”; Letters to the Editor, British Journal of Plastic Surgery, 1998, vol. 51 (3), p. 267; Elsevier Science/The British Association of Plastic Surgeons, UK.
S.E. Greer, et al “The Use of Subatmospheric Pressure Dressing Therapy to Close Lymphocutaneous Fistulas of the Groin” British Journal of Plastic Surgery (2000), vol. 53, pp. 484-487.
George V. Letsou, MD., et al; “Stimulation of Adenylate Cyclase Activity in Cultured Endothelial Cells Subjected to Cyclic Stretch”; Journal of Cardiovascular Surgery, vol. 31, 1990, pp. 634-639.
Orringer, Jay, et al; “Management of Wounds in Patients with Complex Enterocutaneous Fistulas”; Surgery, Gynecology & Obstetrics, Jul. 1987, vol. 165, pp. 79-80.
International Search Report for PCT International Application PCT/GB95/01983; Nov. 23, 1995.
PCT International Search Report for PCT International Application PCT/GB98/02713; Jan. 8, 1999.
PCT Written Opinion; PCT International Application PCT/GB98/02713; Jun. 8, 1999.
PCT International Examination and Search Report, PCT International Application PCT/GB96/02802; Jan. 15, 1998 & Apr. 29, 1997.
PCT Written Opinion, PCT International Application PCT/GB96/02802; Sep. 3, 1997.
Dattilo, Philip P., Jr., et al; “Medical Textiles: Application of an Absorbable Barbed Bi-directional Surgical Suture”; Journal of Textile and Apparel, Technology and Management, vol. 2, Issue 2, Spring 2002, pp. 1-5.
Kostyuchenok, B.M., et al; “Vacuum Treatment in the Surgical Management of Purulent Wounds”; Vestnik Khirurgi, Sep. 1986, pp. 18-21 and 6 page English translation thereof.
Davydov, Yu. A., et al; “Vacuum Therapy in the Treatment of Purulent Lactation Mastitis”; Vestnik Khirurgi, May 14, 1986, pp. 66-70, and 9 page English translation thereof.
Yusupov. Yu. N., et al; “Active Wound Drainage”, Vestnik Khirurgi, vol. 138, Issue 4, 1987, and 7 page English translation thereof.
Davydov, Yu. A., et al; “Bacteriological and Cytological Assessment of Vacuum Therapy for Purulent Wounds”; Vestnik Khirurgi, Oct. 1988, pp. 48-52, and 8 page English translation thereof.
Davydov, Yu. A., et al; “Concepts for the Clinical-Biological Management of the Wound Process in the Treatment of Purulent Wounds by Means of Vacuum Therapy”; Vestnik Khirurgi, Jul. 7, 1980, pp. 132-136, and 8 page English translation thereof.
Chariker, Mark E., M.D., et al; “Effective Management of incisional and cutaneous fistulae with closed suction wound drainage”; Contemporary Surgery, vol. 34, Jun. 1989, pp. 59-63.
Egnell Minor, Instruction Book, First Edition, 300 7502, Feb. 1975, pp. 24.
Egnell Minor: Addition to the Users Manual Concerning Overflow Protection—Concerns all Egnell Pumps, Feb. 3, 1983, p. 1.
Svedman, P.: “Irrigation Treatment of Leg Ulcers”, The Lancet, Sep. 3, 1983, pp. 532-534.
Chinn, Steven D. et al.: “Closed Wound Suction Drainage”, The Journal of Foot Surgery, vol. 24, No. 1, 1985, pp. 76-81.
Arnljots, Bjorn et al.: “Irrigation Treatment in Split-Thickness Skin Grafting of Intractable Leg Ulcers”, Scand J. Plast Reconstr. Surg., vol. 19, 1985, pp. 211-213.
Svedman, P.: “A Dressing Allowing Continuous Treatment of a Biosurface”, IRCS Medical Science: Biomedical Technology, Clinical Medicine, Surgery and Transplantation, vol. 7, 1979, p. 221.
Svedman, P. et al.: “A Dressing System Providing Fluid Supply and Suction Drainage Used for Continuous or Intermittent Irrigation”, Annals of Plastic Surgery, vol. 17, No. 2, Aug. 1986, pp. 125-133.
K.F. Jeter, T.E. Tintle, and M. Chariker, “Managing Draining Wounds and Fistulae: New and Established Methods,” Chronic Wound Care, edited by D. Krasner (Health Management Publications, Inc., King of Prussia, PA 1990), pp. 240-246.
G. {hacek over (Z)}ivadinovic, V. ukić, {hacek over (Z)}. Maksimović, . Radak, and P. Pe{hacek over (s)}ka, “Vacuum Therapy in the Treatment of Peripheral Blood Vessels,” Timok Medical Journal 11 (1986), pp. 161-164 (certified translation).
F.E. E Johnson, “An Improved Technique for Skin Graft Placement Using a Suction Drain,” Surgery, Gynecology, and Obstetrics 159 (1984), pp. 584-585.
A.A. Safronov, Dissertation Abstract, Vacuum Therapy of Trophic Ulcers of the Lower Leg with Simultaneous Autoplasty of the Skin (Central Scientific Research Institute of Traumatology and Orthopedics, Moscow, U.S.S.R. 1967) (certified translation).
M. Schein, R. Saadia, J.R. Jamieson, and G.A.G. Decker, “The ‘Sandwich Technique’ in the Management of the Open Abdomen,” British Journal of Surgery 73 (1986), pp. 369-370.
D.E. Tribble, “An Improved Sump Drain-Irrigation Device of Simple Construction,” Archives of Surgery 105 (1972) pp. 511-513.
C.E. Tennant, “The Use of Hypermia in the Postoperative Treatment of Lesions of the Extremities and Thorax,” Journal of the American Medical Association 64 (1915), pp. 1548-1549.
Selections from W. Meyer and V. Schmieden, Bier's Hyperemic Treatment in Surgery, Medicine, and the Specialties: A Manual of Its Practical Application, (W.B. Saunders Co., Philadelphia, PA 1909), pp. 17-25, 44-64, 90-96, 167-170, and 210-211.
V.A. Solovev et al., Guidelines, The Method of Treatment of Immature External Fistulas in the Upper Gastrointestinal Tract, editor-in-chief Prov. V.I. Parahonyak (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1987) (“Solovev Guidelines”).
V.A. Kuznetsov & N.A. Bagautdinov, “Vacuum and Vacuum-Sorption Treatment of Open Septic Wounds,” in II All-Union Conference on Wounds and Wound Infections: Presentation Abstracts, edited by B.M. Kostyuchenok et al. (Moscow, U.S.S.R. Oct. 28-29, 1986) pp. 91-92 (“Bagautdinov II”).
V.A. Solovev, Dissertation Abstract, Treatment and Prevention of Suture Failures after Gastric Resection (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1988) (“Solovev Abstract”).
V.A.C.® Therapy Clinical Guidelines: A Reference Source for Clinicians (Jul. 2007).
Related Publications (1)
Number Date Country
20140058345 A1 Feb 2014 US
Provisional Applications (1)
Number Date Country
61423405 Dec 2010 US
Divisions (1)
Number Date Country
Parent 13316997 Dec 2011 US
Child 14015385 US